Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) . criteria; baseline measurements and evaluations of all sites of disease must be obtained within  weeks prior to randomization and must be acquired by multiphasic computed tomography (CT) or contrast magnetic resonance imaging (MRI)\r\n* NOTE: positron emission tomography (PET)-CT scans are allowed provided the CT portion of the exam is equivalent to a diagnostic CT scan and includes both oral and IV contrast
Has at least one measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI), according to Response Evaluation Criteria in Solid Tumors (RECIST) Version ..
At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) . that can be followed by computed tomography (CT) or magnetic resonance imaging (MRI)
Participants must have at least one lesion that is not within a previously radiated field that is measurable on computerized tomography (CT) or magnetic resonance imaging (MRI) scan per Response Evaluation Criteria in Solid Tumors (RECIST) version .; bone lesions are not considered measurable by definition
Has ? distant and/or discrete non-injected lesion that is amenable to biopsy via visual inspection or amenable to biopsy via image guidance, such as ultrasound or computed tomography/magnetic resonance imaging (CT/MRI). This lesion must be measurable as defined by the response criteria used to assess the participant (Response Evaluation Criteria in Solid Tumors version . [RECIST .] for solid tumors or revised International Working Group [IWG] criteria for lymphomas).
At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) . which can be followed by computed tomography (CT) or magnetic resonance imaging (MRI).
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) . criteria; radiographic tumor assessment performed within  days before treatment; target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site after the completion of radiation therapy
In dose expansion, at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) . which can be followed by CT or magnetic resonance imaging (MRI)
Subjects must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) . criteria. Radiographic tumor assessment performed within  days of study inclusion.
Presence of measurable disease by computed tomography (CT) scan per Response Evaluation Criteria in Solid Tumors (RECIST) version (v).
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) . criteria
>=  evaluable site of disease measuring >= . cm in diameter on computed tomography (CT) or magnetic resonance imaging (MRI) as measured per Response Evaluation Criteria in Solid Tumors (RECIST)
At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version . criteria that has not been previously irradiated and which can be followed by computed tomography (CT) or magnetic resonance imaging (MRI)
At least one site of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) . criteria on computed tomography (CT) scan done within  days prior to study start
INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Patients must have measurable disease by at least one of the criteria below:\r\n* Extra skeletal disease that can be accurately measured in at least one dimension as >=  mm with conventional computed tomography (CT) techniques as defined by Response Evaluation Criteria in Solid Tumors (RECIST) .\r\n* Skeletal or bone-only disease measurable by fludeoxyglucose F  (FDG) positron emission tomography (PET) imaging
Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v). (at least one lesion >= mm in at least one dimension when assessed by computed tomography [CT] or magnetic resonance imaging [MRI], or a cutaneous lesion with clearly defined margins that measures >=  mm in at least one dimension)
At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v). on screening computed tomography (CT) or magnetic resonance imaging (MRI)
Patients must have documentation of relapse that includes either doubling of CA serum levels confirmed by measurements greater than one week apart or identification of a new measurable lesion greater than  cm in the peritoneal cavity either by computed tomography/magnetic resonance imaging (CT/MRI), positron emission tomography (PET)/CT scan or physical exam (expanding pockets of ascites fluid that may serve as an alternative source of tumor cells) if the index lesion is not accessible for biopsy for vaccine formulation; recurrence outside the peritoneal cavity will be accessed using standard Response Evaluation Criteria in Solid Tumors (RECIST) criteria
At least one measurable lesion as assessed by computed tomography (CT) scan using Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable disease determined using guidelines of Response Evaluation Criteria in Solid Tumors (RECIST) .; baseline tumor assessment should be performed using high resolution computed tomography (CT) scans or magnetic resonance imaging (MRI)
Histologically proven metastatic pancreatic or colorectal adenocarcinoma with measurable disease, defined as at least  unidimensionally measurable lesion on a computed tomography (CT) scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) . criteria
Bi-dimensionally measurable disease by radiographic imaging (computed tomography [CT] scan) that represents at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version (v).
Patients must have a clinically measurable primary oropharyngeal tumor, defined as measuring >=  cm by spiral computed tomography (CT), per Response Evaluation Criteria In Solid Tumors (RECIST) ., and/or by clinical examination
Measurable or non-measurable (but radiologically evaluable) disease per Response Evaluation Criteria In Solid Tumors (RECIST), version . on computed tomography (CT) scan (within  days of randomization) with at least one lesion outside previously irradiated areas.
DISEASE RELATED CRITERIA: Patients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI) within  days prior to registration; the CT from a combined positron emission tomography (PET)/CT may be used only if it is of diagnostic quality; non-measurable disease must be assessed within  days prior to registration; all known sites of disease must be assessed and documented on the baseline tumor assessment form (Response Evaluation Criteria in Solid Tumors [RECIST .])
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) ., defined as at least one lesion that can be accurately measured in at least one dimension >=  mm (>=  cm) by computed tomography (CT) imaging or magnetic resonance imaging (MRI) within  days prior to registration; the CT from a combined positron emission tomography (PET)/CT may be used only if it is of diagnostic; laboratory parameters are not acceptable as the only evidence of disease
Participant must have at least  unidimensional measurable NSCLC lesion on a computed tomography (CT) scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version .).
Subject has one or more tumors measurable by computed tomography (CT) scan using Response Evaluation Criteria in Solid Tumors (RECIST) . criteria; magnetic resonance imaging (MRI) is acceptable if a CT scan is contraindicated
Have measurable or nonmeasurable but evaluable disease determined using guidelines in Response Evaluation Criteria in Solid Tumors, Version . (RECIST v .). Baseline tumor assessment should be performed using a high resolution computed tomography (CT) scan using IV and oral contrast unless clinically contra-indicated. Magnetic resonance imaging (MRI) is acceptable if a CT cannot be performed.
Patients must have measurable or non-measurable metastatic disease; computed tomography (CT) scans or magnetic resonance imagings (MRIs) used to assess all disease must have been completed within  days prior to Step  Randomization; CT scans or MRIs must be assessed and documented on the Baseline Tumor Assessment Form (Response Evaluation Criteria in Solid Tumors [RECIST] .)
Patients should have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) . on computed tomography (CT) or magnetic resonance imaging (MRI) that is accessible to biopsy
Patients must have measurable disease according to the standard Response Evaluation Criteria in Solid Tumors (RECIST) version ., computed tomography (CT) scans or magnetic resonance imagings (MRIs) used to assess the measurable disease must have been completed within  days prior to study drug initiation
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) . assessed by computed tomography (CT) scan, or for skin lesions not measurable by CT scan, measurements may be performed with caliper or flexible ruler\r\n* Note: stage IV no evidence of disease (NED) is excluded by this criterion
Subject must have at least  unidimensional measurable NSCLC lesion on a Computerized Tomography (CT) scan as defined by Response Evaluation Criteria In Solid Tumors (RECIST - version .).
Measurable disease by Computed tomography (CT) or Magnetic resonance imaging (MRI) per Response Evaluation Criteria In Solid Tumors (RECIST .) criteria
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per response evaluation criteria in solid tumors version (RECIST) . criteria
Measurable disease by computed tomography (CT) by Response Evaluation Criteria in Solid Tumors (RECIST) . to evaluate response
At least  lesion on a computed tomography (CT) scan that is measurable as defined by Response Evaluation Criteria In Solid Tumors (RECIST), Version ..
Patient must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) . criteria; baseline measurements and evaluations of all sites of disease must be obtained =<  weeks prior to randomization and must be acquired by multiphasic CT or contrast magnetic resonance imaging (MRI)
Measurable disease by computed tomography (CT)/magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) . criteria
Patient must have at least  site of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) . criteria on computed tomography (CT) or magnetic resonance imaging (MRI) which will not be irradiated
At least  solid tumor lesion measurable by computer tomography (CT) scan or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST) version .
Subjects must have at least two lesions:\r\n* At least one lesion must be safely amenable to irradiation and likely to meet criteria delineated in the judgement of the treating radiation oncologist; this can be a lesion that was previously irradiated as long as prior radiation was at least  months prior to projected first fraction of SBRT and as long as reirradiation dose constraints as outlined are being met\r\n* A separate, not-to-be-irradiated lesion measurable by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria In Solid Tumors (RECIST) . criteria
Histologically proven pancreatic adenocarcinoma with measurable disease, defined as at least  unidimensionally measurable lesion on a computed tomography (CT) scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) . criteria
Stage IV disease as evidenced by soft tissue, visceral and/or bony metastasis must be Response Evaluation Criteria in Solid Tumors (RECIST) evaluable on computed tomography (CT) scan and/or bone scan
Patients must have measurable disease either primary and/or metastatic masses reproducibly measurable in one or two diameters by Response Evaluation Criteria in Solid Tumors (RECIST) criteria . parameters by CT scan or MRI scan; positron emission tomography (PET) or octreotide scans are useful adjuncts but will not be used to measure response
Patients must have computed tomography (CT) measurable disease as defined by Response Evaluation Criteria in Solid Tumors version . (RECIST v.)
At least one measurable lesion at baseline by CT (computed tomography) or MRI (magnetic resonance imaging) as per RECIST (Response Evaluation Criteria In Solid Tumors) v.
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) ., defined as at least one lesion that can be accurately measured in at least one dimension >=  mm (>=  cm) by computed tomography (CT) imaging or magnetic resonance imaging (MRI) within  days prior to start of protocol therapy; the CT from a combined positron emission tomography (PET)/CT may be used if it is of diagnostic quality; laboratory parameters are not acceptable as the only evidence of disease
Patients must have either measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] .) or evaluable disease (non-measurable lesions) outside irradiated field on computed tomography (CT)/magnetic resonance imaging (MRI)
At least one site of measurable disease (per Response Evaluation Criteria in Solid Tumors [RECIST] .) that is seen on CT, magnetic resonance imaging (MRI), or FDG PET/CT
Subjects must have measurable disease by CT or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) . criteria; to comply with PET Response Criteria in Solid Tumors (PERCIST) criteria, subjects should have at least one lesion measuring at least  cm in the longest diameter
Subjects must have at least one measurable lesion at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) . criteria